The device at the heart of the study is a deterministic lateral displacement, or DLD, microfluidic chip, a technology first demonstrated in the early 2000s. A DLD device is essentially a dense forest of tiny pillars arranged in tilted rows. As blood flows through the array, particles smaller than a critical size follow the fluid streamlines and pass straight through, while particles larger than that threshold are nudged sideways each time they collide with a pillar. Because the displacement is deterministic rather than diffusive, the device can continuously sort cells by size without any chemical labels, antibodies, or centrifugation. That makes DLD attractive for liquid biopsies, where the goal is to pluck tumor cells from a blood sample while leaving red blood cells and white blood cells behind.

The catch is that DLD performance depends on a tangle of coupled variables. The gap between pillars, the tilt angle of the post array, and the flow rate of the sample all interact in nonlinear ways to determine how far a target cell is displaced laterally. A small change in one parameter can shift the effective critical diameter that separates tumor cells from blood cells, and a change in another can amplify or suppress that effect. Traditionally, engineers have navigated this design space by trial and error, running simulation after simulation or fabricating chip after chip. Each evaluation is computationally expensive, and brute-force parametric sweeps offer little insight into how the parameters actually interact with one another.

The research team, led by Sadia Anjum Mim and corresponding author Xiaolin Chen, with Mohammed Raihan Uddin as a co-author, replaced that brute-force search with Bayesian optimization. The approach treats each simulation of the DLD device as an expensive black-box function whose output is the lateral displacement of the target particle. Instead of blindly sampling the design space, Bayesian optimization builds a Gaussian process surrogate model, a probabilistic statistical model that learns the relationship between the design variables and the displacement response. The Gaussian process not only predicts the displacement for any candidate design but also quantifies how uncertain that prediction is. An acquisition function then uses both the prediction and the uncertainty to decide where to sample next, balancing exploration of poorly understood regions against exploitation of promising ones.

The team used three design variables in the optimization: the pillar gap size, the tilt parameter of the post array, and the flow rate. Each candidate design was evaluated with detailed numerical simulations of the fluid and particle dynamics, and the results fed back into the surrogate model, which grew more accurate with every iteration. The final Gaussian process model achieved a coefficient of determination, R-squared, of 0.9873 on an independent validation dataset, with a mean absolute error of just 1.24 micrometers. In practical terms, the surrogate could predict how far a target cell would be pushed sideways by a given chip design with remarkable fidelity, without needing to run the full simulation every time.

The efficiency gains were striking. When the researchers compared Bayesian optimization against an Evolution Strategy benchmark, the Bayesian approach needed 67.2 percent fewer evaluations to identify the best-performing design within the prescribed design space and cut the time to solution by 80.0 percent. It also outperformed Genetic Algorithms, Differential Evolution, Particle Swarm Optimization, and conventional parametric sweeps. Because each evaluation of the underlying simulation is costly, reducing the number of required evaluations translates directly into days or weeks of saved computation, and it opens the door to exploring design spaces that would be intractable with exhaustive methods.

The winning design identified by the optimizer produced a target-particle lateral displacement of 75.51 micrometers. Follow-up analyses of particle size and outlet regions revealed an effective critical diameter of approximately 11.4 micrometers, a threshold that cleanly separates the investigated non-small-cell lung cancer CTC surrogate from smaller blood-cell-relevant background particles. The team demonstrated distinct collection of the target and background particles across three different release positions, meaning the separation remained robust regardless of where cells entered the device. That kind of positional robustness matters in a real clinical sample, where cells arrive at the chip inlet distributed across the full width of the channel rather than in a tidy single stream.

Beyond finding a single optimal design, the Gaussian process surrogate turned out to be a rich analytical tool in its own right. Because the model covers the entire design space, it enables response-surface mapping, which visualizes how displacement varies across combinations of parameters. It also supports global sensitivity analysis, which quantifies how much each design variable contributes to the output. The analysis identified the post-array tilt parameter as the dominant factor governing target-particle lateral displacement, while the flow rate was found to interact strongly with the geometric variables. That interaction is precisely the kind of insight that trial-and-error approaches miss, and it gives device designers a physical intuition about which knobs matter most and how they couple.

The framework also incorporates uncertainty quantification, a feature that distinguishes it from many purely data-driven design pipelines. Uncertainty analysis confirmed that the optimized device maintains stable performance under perturbations, meaning that small manufacturing imperfections or operating fluctuations are unlikely to destroy the separation quality. For microfluidic devices that must eventually be fabricated at scale and operated outside pristine laboratory conditions, this reliability-aware perspective is essential. A design that performs brilliantly only at one exact point in parameter space is of limited clinical value; one that tolerates realistic variation is far more likely to survive the journey from simulation to bedside.

The broader implications extend past cancer diagnostics. DLD devices have been used to separate parasites from blood, fractionate blood components, and sort particles across a wide range of sizes, and the optimization framework described here is general enough to be applied to any of these applications. By making the design process faster, more interpretable, and more reliable, Bayesian optimization could accelerate the development of an entire family of label-free cell-sorting chips. For liquid biopsy, in particular, the prospect of a cheap, antibody-free, continuously operating chip that reliably isolates circulating tumor cells is compelling, and this study demonstrates that intelligent algorithmic design, rather than exhaustive manual tuning, may be the fastest route to getting there. The work was supported in part by the National Science Foundation under Grant No. 2243980.

Subject of Research: Machine learning-driven optimization of microfluidic deterministic lateral displacement devices for label-free circulating tumor cell separation

Article Title: Bayesian optimization of deterministic lateral displacement devices for circulating tumor cell separation

Article References: Mim, S. A., Uddin, M. R., & Chen, X. (2026). Bayesian optimization of deterministic lateral displacement devices for circulating tumor cell separation. Biomedical Microdevices, 28(4), Article 72. https://doi.org/10.1007/s10544-026-00856-4

Image Credits: AI Generated

DOI: 10.1007/s10544-026-00856-4

Keywords: Bayesian optimization, Gaussian process, deterministic lateral displacement, circulating tumor cells, microfluidics, liquid biopsy, surrogate modeling, cell separation, uncertainty quantification, sensitivity analysis, biomedical microdevices, machine learning